1 min readAllosteric Inhibition Reveals SHP2-Mediated Tumour Immunosuppression in Colon Cancer by Single-Cell Transcriptomics
Nanjing, China — Colorectal cancer (CRC), a malignant tumour worldwide consists of microsatellite instability (MSI) and stable (MSS) phenotypes. Although SHP2 is a hopeful target for cancer therapy, its relationship with innate immunosuppression remains elusive. To address that, the authors of this article performed single-cell RNA sequencing to explore the role of SHP2 in all cell types of tumour microenvironment (TME) from murine MC38 xenografts. Intratumoral cells were found to be functionally heterogeneous and responded significantly to SHP099, a SHP2 allosteric inhibitor. The malignant evolution of tumor cells was remarkably arrested by SHP099. Mechanistically, STING-TBK1-IRF3-mediated type I interferon signaling was highly activated by SHP099 in infiltrated myeloid cells. Notably, CRC patients with MSS phenotype exhibited greater macrophage infiltration and more potent SHP2 phosphorylation in CD68+ macrophages than MSI-high phenotypes, suggesting the potential role of macrophagic SHP2 in TME.
Collectively, the authors data reveals a mechanism of innate immunosuppression mediated by SHP2, suggesting that SHP2 is a promising target for colon cancer immunotherapy.
Article adapted from a Compuscript Ltd news release.
Publication: Allosteric inhibition reveals SHP2-mediated tumor immunosuppression in colon cancer by single-cell transcriptomics. Gao, J et al. Acta Pharmaceutica Sinica B (August 11, 2021): Click here to view.